Related Experiment Video

Updated: Sep 4, 2025

Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease
07:21

Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease

Published on: June 16, 2023

1.0K

[Pharmacological treatment of cardiovascular diseases in old age : Geriatic perspective]

Markus Gosch1

  • 1Klinikum Nürnberg, Medizinische Klinik 2 - Schwerpunkt Geriatrie, Paracelsus Medizinische Privatuniversität Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland. markus.gosch@klinikum-nuernberg.de.

Zeitschrift Fur Gerontologie Und Geriatrie
|July 18, 2022
PubMed

Insights

Older adults have high rates of cardiovascular disease but are often excluded from clinical trials, leading to insufficient evidence for their treatment. Geriatric pharmacotherapy requires individualized approaches for complex cardiovascular conditions.

Area of Science:

  • Geriatrics
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular diseases (CVD) are most prevalent in older adults.
  • Older populations are underrepresented in randomized controlled trials (RCTs).
  • This leads to insufficient evidence for guideline recommendations in geriatric patients.

Purpose of the Study:

  • To discuss the pharmacotherapy of relevant cardiovascular diseases.
  • To adopt a geriatric treatment approach.
  • To highlight the need for individualized pharmacological therapy in elderly patients.

Main Methods:

  • Review of current literature on cardiovascular pharmacotherapy in the elderly.
  • Analysis of treatment guidelines considering geriatric complexities.
  • Focus on individualized pharmacological strategies.

Main Results:

  • Evidence for CVD treatment in older adults is often limited due to trial underrepresentation.
  • Geriatric patients present unique complexities and vulnerabilities.
  • Individualized pharmacotherapy is crucial for effective and safe treatment.

Conclusions:

  • Standard treatment guidelines may not be directly applicable to older adults.
  • A tailored geriatric approach is necessary for cardiovascular pharmacotherapy.
  • Individual patient factors must guide pharmacological decisions in the elderly.

Keywords:
EthicsGeriatricsHeart failureHypertensionOral anticoagulation

More Related Videos

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

12.7K
Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease10:19

Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease

Published on: August 22, 2014

14.3K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
501
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
429